Related Experiment Video
Updated: Jul 4, 2025
05:39
Detection of MicroRNA Expression in the Kidneys of Immunoglobulin A Nephropathic Mice
Published on: July 8, 2020
1.9K
[Immunoglobulin A nephropathy-New treatment possibilities]
1Klinik für Innere Medizin II, Martin-Luther-Universität Halle-Wittenberg, Ernst-Grube-Str. 40, 06120, Halle (Saale), Deutschland. matthias.girndt@uk-halle.de.
Innere Medizin (Heidelberg, Germany)
|January 31, 2024
Summary
Immunoglobulin A (IgA) nephropathy, a common kidney disease, can be managed by controlling blood pressure and avoiding toxins. Newer treatments like SGLT-2 inhibitors and immunomodulators show promise in slowing disease progression.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Context:
- Immunoglobulin A (IgA) nephropathy is the most common glomerulonephritis in adults in Central Europe.
- It presents with hematuria, proteinuria, and progressive kidney function loss.
- Diagnosis relies on kidney biopsy.
Purpose:
- To review current and emerging pharmacotherapies for IgA nephropathy.
- To highlight the efficacy of SGLT-2 inhibitors and budesonide formulations.
- To discuss novel treatments in clinical trials.
Summary:
- Standard care involves blood pressure control, angiotensin inhibitors, and avoiding nephrotoxins.
- Sodium-glucose transporter 2 (SGLT-2) inhibitors significantly reduce proteinuria and slow eGFR decline.
- A specific budesonide formulation is effective, while systemic corticosteroids are rarely used.
Impact:
- SGLT-2 inhibitors and immunomodulators represent significant advancements in IgA nephropathy treatment.
- Emerging therapies like sparsentan and sibeprenlimab show potential to expand future treatment options.
- These advancements aim to slow kidney damage and improve patient outcomes.
Keywords:
BudesonideGlomerulonephritisImmunosuppression therapyKidney failure, chronicSodium-glucose transporter 2 (SGLT-2) inhibitorsMore Related Videos
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
137
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
137
01:27Tumor Immunotherapy
526
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
526
01:27Open Angle Glaucoma: Treatment
452
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
452